2022-11-17 | NDAQ:CMRA | Press release

WOBURN, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic drugs to improve patient access, safety and convenience, today announced that it will participate in Benchmark Company’s 11the The annual Discovery One-on-One Investor Conference will be held on Thursday, December 1, 2022 at the New York Athletic Club in New York City.

Interested parties can access a copy of Comera’s current investor presentation https://ir.comeralifesciences.com/

About Comera Life Sciences

Leading a compassionate new era in medicine, Comera Life Sciences applies deep knowledge of formulation science and technology to transform essential biological medicines from intravenous (IV) forms to subcutaneous (SQ) forms that can be self-administered. The goal of this approach is to offer patients the freedom of self-injectable care, reduce institutional dependency, and put patients at the center of their treatment regimen.

To learn more about the Comera Life Sciences mission, as well as the proprietary SQore™ platform, visit https://comeralifesciences.com/.


Comera Investor

John Woolford

ICR Westwicke

[email protected]

Comera Press

Jon Yu

ICR Westwicke

[email protected]

main logo

Comments are closed.